Orthofix Earnings Call Shows Growth Amid Spine Challenges
Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

